Monash University
The results from a Phase 1 clinical trial led by the University of California published today in Nature Medicine has found a single dose of the psychedelic substance psilocybin, administered alongside psychological support, is a safe and acceptable treatment for patients with anorexia nervosa and may decrease eating-disorder behaviours in a subset of patients.
Professor Chris Langmead from the Monash Institute of Pharmaceutical Sciences is
/Public Release.
